Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Sep;38(9):1818-1827.
doi: 10.1111/jdv.19996. Epub 2024 Apr 10.

Dermatological manifestations in Costello syndrome: A prospective multicentric study of 31 HRAS-positive variant patients

Affiliations
Multicenter Study

Dermatological manifestations in Costello syndrome: A prospective multicentric study of 31 HRAS-positive variant patients

Didier Bessis et al. J Eur Acad Dermatol Venereol. 2024 Sep.

Abstract

Background: Data on dermatological manifestations of Costello syndrome (CS) remain heterogeneous and lack in validated description.

Objectives: To describe the dermatological manifestations of CS; compare them with the literature findings; assess those discriminating CS from other RASopathies, including cardiofaciocutaneous syndrome (CFCS) and the main types of Noonan syndrome (NS); and test for dermatological phenotype-genotype correlations.

Methods: We performed a 10-year, large, prospective, multicentric, collaborative dermatological and genetic study.

Results: Thirty-one patients were enrolled. Hair abnormalities were ubiquitous, including wavy or curly hair and excessive eyebrows, respectively in 68% and 56%. Acral excessive skin (AES), papillomas and keratotic papules (PKP), acanthosis nigricans (AN), palmoplantar hyperkeratosis (PPHK) and 'cobblestone' papillomatous papules of the upper lip (CPPUL), were noted respectively in 84%, 61%, 65%, 55% and 32%. Excessive eyebrows, PKP, AN, CCPUL and AES best differentiated CS from CFCS and NS. Multiple melanocytic naevi (>50) may constitute a new marker of attenuated CS associated with intragenic duplication in HRAS. Oral acitretin may be highly beneficial for therapeutic management of PPHK. No significant dermatological phenotype-genotype correlation was determined between patients with and without HRAS c.34G>A (p.G12S).

Conclusions and relevance: This validated phenotypic characterization of a large number of patients with CS will allow future researchers to make a positive diagnosis, and to differentiate CS from CFCS and NS.

PubMed Disclaimer

References

REFERENCES

    1. Gripp KW, Morse LA, Axelrad M, Chatfield KC, Chidekel A, Dobyns W, et al. Costello syndrome: clinical phenotype, genotype, and management guidelines. Am J Med Genet A. 2019;179:1725–1744.
    1. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto‐oncogene cause Costello syndrome. Nat Genet. 2005;37:1038–1040.
    1. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Nihori T, et al. Cardio‐facio‐cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype‐phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007;44:763–771.
    1. Gelb BD, Cavé H, Dillon MW, Gripp KW, Lee JA, Mason‐Suares H, et al. ClinGen's RASopathy expert panel consensus methods for variant interpretation. Genet Med. 2018;20:1334–1345.
    1. Morice‐Picard F, Ezzedine K, Delrue MA, Arveiler B, Fergelot P, Taïeb A, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol. 2013;30:665–673.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources